公开(公告)号：EP2283028A2

公开(公告)日：2011-02-16

申请号：EP08797529.8

申请日：2008-08-08

申请人： The Board of Regents of The University of Texas System ,  Universidade Federal Do Rio De Janeiro

发明人： PASQUALINI, Renata ,  ARAP, Wadih ,  GIORDANO, Ricardo ,  CARDO-VILA, Marina ,  VALENTE, Ana Paula ,  CENEVIVA LACERDA DE ALMEIDA, Fabio

IPC分类号： C07K5/08

CPC分类号： C12N15/62 ,  A61K47/66 ,  B82Y5/00 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0817 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001

摘要： The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly
D (LPR), that selectively target VEGFR-1 and NRP-1 expressing cells. Targeted molecules in accordance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.

摘要翻译： 本发明涉及治疗剂的分子医学和靶向递送领域。 更具体地说，本发明涉及鉴定选择性靶向VEGFR-1和NRP-1表达细胞的结合了氨基酸Leu-Pro-Arg（LPR），特别是D（LPR）的新肽序列。 根据本发明的靶向分子可用于治疗和检测新生血管或血管生成性VEGF相关病症，包括但不限于癌症，肥胖症，糖尿病，哮喘，关节炎，肝硬化和眼部疾病。